Status:
COMPLETED
Efficacy of Treatment Intensification With Maraviroc on HIV-1 Viral Latency in Recently Infected Hiv-1 naïve Patients Starting Raltegravir Plus Tenofovir/Emtricitabine
Lead Sponsor:
Germans Trias i Pujol Hospital
Conditions:
HIV Infections
Eligibility:
All Genders
18-99 years
Phase:
PHASE3
Brief Summary
The intensification with maraviroc in recently HIV-1-infected patients of a preferred gold-standard triple therapy composed of raltegravir plus tenofovir/emtricitabine could accelerate the decay of th...
Detailed Description
A reservoir of latently infected cells established early in infection may be involved in the maintenance of viral persistence despite continuous highly active antiretroviral therapy (HAART). This is l...
Eligibility Criteria
Inclusion
- HIV-1 infected adults (\>=18 years old).
- No previous antiretroviral therapy for more than 2 weeks.
- HIV-1 infection documented in the past 6 months by a previous negative ELISA test, or a documented clinical acute seroconversion in the past 6 months.
- CCR5-tropism confirmed at screening.
- Voluntary written informed consent.
Exclusion
- Pregnancy or fertile women willing to be pregnant.
- Active substance abuse or major psychiatric disease.
- Presence of NRTI mutations in the screening genotype.
Key Trial Info
Start Date :
February 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2011
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00808002
Start Date
February 1 2009
End Date
November 1 2011
Last Update
January 31 2020
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Germans Trias i Pujol
Badalona, Barcelona, Spain, 08916
2
Hospital Clinic i Provincial de Barcelona
Barcelona, Spain, 08916